title: Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins.
abstract: The mechanism by which the drug rapamycin inhibits the mechanistic target of rapamycin (mTOR) is of intense interest because of its likely relevance in cancer biology, aging, and other age-related diseases. While rapamycin acutely and directly inhibits mTORC1, only chronic administration of rapamycin can inhibit mTORC2 in some, but not all, cell lines or tissues. The mechanism leading to cell specificity of mTORC2 inhibition by rapamycin is not understood and is especially important because many of the negative metabolic side effects of rapamycin, reported in mouse studies and human clinical trials, have been attributed recently to mTORC2 inhibition. Here, we identify the expression level of different FK506-binding proteins (FKBPs), primarily FKBP12 and FKBP51, as the key determinants for rapamycin-mediated inhibition of mTORC2. In support, enforced reduction of FKBP12 completely converts a cell line that is sensitive to mTORC2 inhibition to an insensitive cell line, and increased expression can enhance mTORC2 inhibition. Further reduction of FKBP12 in cell lines with already low FKBP12 levels completely blocks mTORC1 inhibition by rapamycin, indicating that relative FKBP12 levels are critical for both mTORC1 and mTORC2 inhibition, but at different levels. In contrast, reduction of FKBP51 renders cells more sensitive to mTORC2 inhibition. Our findings reveal that the expression of FKBP12 and FKBP51 is the rate limiting factor that determines the responsiveness of a cell line or tissue to rapamycin. These findings have implications for treating specific diseases, including neurodegeneration and cancer, as well as targeting aging in general.
authors: The Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA, 94945, USA.
authors: Katherine H
authors: KH
authors: Schreiber
authors: Denise
authors: D
authors: Ortiz
authors: Emmeline C
authors: EC
authors: Academia
authors: Arieanna C
authors: AC
authors: Anies
authors: Chen-Yu
authors: CY
authors: Liao
authors: Brian K
authors: BK
authors: Kennedy
mesh_terms: D000367:Age Factors; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D057809:HEK293 Cells; D006367:HeLa Cells; D006801:Humans; D000076225:Mechanistic Target of Rapamycin Complex 2; D051379:Mice; D046912:Multiprotein Complexes / Q000037:antagonists & inhibitors* / Q000378:metabolism; D020123:Sirolimus / Q000494:pharmacology*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D022021:Tacrolimus Binding Proteins / Q000096:biosynthesis* / Q000378:metabolism
chemical_list: D000903:Antibiotics, Antineoplastic; D046912:Multiprotein Complexes; D000076225:Mechanistic Target of Rapamycin Complex 2; D058570:TOR Serine-Threonine Kinases; D022021:Tacrolimus Binding Proteins; D020123:Sirolimus
keywords: FKBP; aging; mTOR; rapamycin
references: Aging Cell. 2013 Oct;12(5):851-62
references: 23734717
references: PLoS Genet. 2013;9(8):e1003708
references: 23990801
references: Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9
references: 11504908
references: Cell. 2002 Jul 26;110(2):163-75
references: 12150925
references: Nature. 2003 Dec 11;426(6967):620
references: 14668850
references: Curr Biol. 2004 May 25;14(10):885-90
references: 15186745
references: J Cell Biol. 2004 Jul 19;166(2):213-23
references: 15249583
references: Sci Aging Knowledge Environ. 2004 Sep 8;2004(36):PE34
references: 15356349
references: Science. 1991 Aug 23;253(5022):905-9
references: 1715094
references: Biochem Biophys Res Commun. 1997 Mar 17;232(2):437-43
references: 9125197
references: Acta Crystallogr D Biol Crystallogr. 1999 Apr;55(Pt 4):736-44
references: 10089303
references: Mech Ageing Dev. 2005 Apr;126(4):491-504
references: 15722108
references: Science. 2005 Nov 18;310(5751):1193-6
references: 16293764
references: Genes Dev. 2006 Jan 15;20(2):174-84
references: 16418483
references: Mol Cell. 2006 Apr 21;22(2):159-68
references: 16603397
references: Aging Cell. 2007 Feb;6(1):95-110
references: 17266679
references: Aging Cell. 2007 Feb;6(1):111-9
references: 17266680
references: Mol Pharmacol. 2008 Apr;73(4):1052-63
references: 18199701
references: Diabetes. 2008 Apr;57(4):945-57
references: 18174523
references: Am J Transplant. 2009 Mar;9(3):558-66
references: 19260835
references: Nature. 2009 Jul 16;460(7253):392-5
references: 19587680
references: Mol Cell Biol. 2009 Nov;29(21):5657-70
references: 19720745
references: Science. 2009 Oct 2;326(5949):140-4
references: 19797661
references: Biochim Biophys Acta. 2009 Oct;1790(10):1067-74
references: 19539012
references: Sci Signal. 2009;2(98):ra75
references: 19934433
references: Cell Metab. 2010 Jan;11(1):35-46
references: 20074526
references: Mol Cell Biol. 2010 Feb;30(4):908-21
references: 19995915
references: Diabetes. 2010 Jun;59(6):1338-48
references: 20299475
references: Cell Metab. 2010 Jun 9;11(6):453-65
references: 20519118
references: Philos Trans R Soc Lond B Biol Sci. 2011 Jan 12;366(1561):17-27
references: 21115526
references: Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35
references: 21157483
references: J Clin Invest. 2011 Apr;121(4):1231-41
references: 21490404
references: Science. 2012 Mar 30;335(6076):1638-43
references: 22461615
references: Cell. 2012 Apr 13;149(2):274-93
references: 22500797
references: Mol Cell Biol. 2013 Apr;33(7):1357-67
references: 23358420
references: Nat Cell Biol. 2013 Jun;15(6):555-64
references: 23728461
references: Science. 2001 Apr 13;292(5515):288-90
references: 11292860